JP Morgan Chase
ESPR

JP Morgan Chase’s Esperion Therapeutics ESPR Stock Holding History

JP Morgan Chase’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,000
Closed -$56K – 6560
2022
Q1 		$56K Buy
+12,000
New +$51.5K ﹤0.01% 5756
2020
Q3 		– Sell
-129,300
Closed -$6.63M – 5542
2020
Q2 		$6.63M Buy
+129,300
New +$5.41M ﹤0.01% 2240
2018
Q3 		– Sell
-84,000
Closed -$3.29M – 5705
2018
Q2 		$3.29M Buy
+84,000
New +$4.24M ﹤0.01% 3011
2018
Q1 		– Sell
-45,000
Closed -$2.96M – 5454
2017
Q4 		$2.96M Buy
+45,000
New +$2.42M ﹤0.01% 3069

Other funds holding ESPR

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $2.17B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return